文献速递免疫规划

结构引导设计广谱交叉反应多价A组链球菌疫苗

Structure-guided design of a broadly cross-reactive multivalent group a streptococcal vaccine.
PubMed 文献 · Vaccine · 2023-08-16

研究应用肽结构算法预测117个N端M肽的免疫交叉反应,结合全球M型流行数据构建含32价M肽的4蛋白重组疫苗;兔免疫后对31/32(97%)疫苗肽和28/37(76%)预测交叉反应肽产生显著抗体,并促进调理吞噬杀伤,预估全球覆盖率约90%(非洲68%至北美95%)。

要点

  • 基于结构算法从117个N端M肽中预测交叉反应,构建32价疫苗(19个交叉反应候选+13个型特异性肽)。
  • 兔免疫后抗体对31/32(97%)疫苗肽和28/37(76%)预测交叉反应肽达显著水平。
  • 疫苗抗血清促进疫苗株及交叉反应M型的调理吞噬杀伤,预估全球覆盖率约90%。

核心结论

  • 结果表明基于结构的设计可用于未来广谱保护性M肽疫苗研究。

研究设计与样本

  • 应用 refined 肽结构算法预测117个代表A组链球菌最常见M型的N端M肽间的免疫交叉反应,结合全球M型流行数据构建32价4蛋白重组疫苗,并在兔中评估免疫原性与调理吞噬杀伤。

主要发现

  • 32价疫苗含19个预测与37个异源M肽交叉反应的候选肽,另加13个型特异性M肽。
  • 兔免疫后对31/32(97%)疫苗肽和28/37(76%)预测交叉反应肽产生显著水平抗体。
  • 疫苗抗血清促进疫苗M型及交叉反应M型A组链球菌的调理吞噬杀伤。
  • 基于近期M型流行分析,32价疫苗潜在全球覆盖率约90%,范围从非洲68%至北美95%。

关键数值与推荐

  • 疫苗为32价,含19个交叉反应候选肽和13个型特异性M肽,为4蛋白重组疫苗。
  • 免疫原性:抗体对31/32(97%)疫苗肽和28/37(76%)预测交叉反应肽达显著水平。
  • 潜在全球覆盖率约90%,非洲68%至北美95%。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The M protein of group A streptococci (Strep A) is a major virulence determinant and protective antigen. The N-terminal region of the M protein is variable in sequence, defines the M/emm type, and contains epitopes that elicit opsonic antibodies that protect animals from challenge infections. Although there are >200 M types of Strep A, there is now evidence that structurally related M proteins can be grouped into clusters and that immunity may be cluster-specific in addition to M type-specific. This observation has led to recent studies of structure-based design of multivalent M peptide vaccines to select peptides predicted to cross-react with heterologous M types to improve vaccine coverage. In the current study, we have applied a refined series of peptide structural algorithms to predict immunological cross-reactivity among 117 N-terminal M peptides representing the most prevalent M types of Strep A. Based on the results of the structural analyses, in combination with global M type prevalence data, we constructed a 32-valent vaccine containing 19 cross-reactive vaccine candidates predicted to cross-react with 37 heterologous M peptides to which were added 13 type-specific M peptides. The 4-protein recombinant vaccine was immunogenic in rabbits and elicited significant levels of antibodies against 31/32 (97%) vaccine peptides and 28/37 (76%) peptides predicted to cross-react. The vaccine antisera also promoted opsonophagocytic killing of vaccine and cross-reactive M types of Strep A. Based on a recent analysis of M type prevalence of Strep A, the potential global coverage of the 32-valent vaccine is ∼90%, ranging from 68% in Africa to 95% in North America. Our results indicate the utility of structure-based design that may be applied to future studies of broadly protective M peptide vaccines.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Dale JB, Aranha MP, Penfound TA, et al. Structure-guided design of a broadly cross-reactive multivalent group a streptococcal vaccine. Vaccine. 2023. PMID: 37596198. doi:10.1016/j.vaccine.2023.08.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。